ESMO Media Releases

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer

Pre-operative treatment with a combination of the immune checkpoint inhibitors nivolumab and ipilimumab achieves major pathological responses

Immunotherapy with nivolumab and low-dose ipilimumab could become a new first line treatment in patients with some metastatic colorectal cancers

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor (TKI), axitinib, significantly improves progression-free survival

Radiotherapy to the prostate improves overall survival in men newly diagnosed with metastatic prostate cancer

Two-year maintenance therapy with olaparib, a PARP inhibitor, olaparib, led to improvement in PFS

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhoea

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer

Arbitrary age limits for participation prevent young patients from entering trials designed for their tumour type

Epigenetic therapy with histone deacetylase (HDAC) inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial (1) reported today at the ESMO 2018 Congress in Munich.

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-)